Finerenone for kidney disease from IgA nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new pill called finerenone to see if it can slow down kidney damage in people with IgA nephropathy, a type of kidney inflammation. If you qualify, you might get finerenone or a placebo, and the study will monitor your kidney health over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- A kidney biopsy within the last 2 years must confirm IgA nephropathy.
- You need to be on a stable dose of blood pressure medication (ACE inhibitor or ARB) for at least 3 months.
- Your urine protein level must be high but not extremely high (between 500 and 3500 mg/g on a urine test).
- Your kidney function must be moderately preserved (eGFR of at least 30).
- Your potassium level must be within a safe range (no higher than 4.8), and your blood pressure must be controlled (systolic under 150, diastolic under 110).
- You must not have used steroids or immune-suppressing drugs in the last 3 months, and you must not have had a kidney transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
This study tests a new medicine called CM313 for people with IgA nephropathy, a kidney disease. The goal is to see if it can help reduce protein in the urine and protect kidney function.
This trial tests whether finerenone can help people with IgA nephropathy, a kidney disease. It is for adults with high protein in their urine who are already on standard kidney-protecting medications.
This trial tests if finerenone can protect kidneys in people with chronic kidney disease who are not taking common blood pressure medications called ACE inhibitors, ARBs, or renin inhibitors. It may help slow kidney damage.
This trial tests a medication called finerenone to see if it can lower the amount of protein in your urine, which is a sign of kidney damage. It is for people with type 2 diabetes and chronic kidney disease who are already on standard blood pressure medications.
This trial tests a new medicine (FXS6837) for people with IgA nephropathy (a kidney disease that causes protein in the urine and can lead to kidney damage). The goal is to see if it can reduce protein loss and protect kidney function.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.